MoA Technology has started developing pesticides and has now been backed by the Parkwalk Opportunities Fund.

GV has joined the investors in oncology treatment developer Relay Therapeutics, which has now raised $120m altogether.

Quantum Motion hopes to use a power-efficient processing architecture to scale up its system so that it can process large numbers.

Liversidge has been on the board of commercialisation firm IP Group since it bought its peer Fusion IP in 2014.

The surgical robot spinout from University of Nebraska will use the series B financing, co-led by SinoPharm, to support it through its application for market clearance.

Remynd could receive as much as $413m from healthcare firm Novo Nordisk if its ReS39 diabetes treatment is proven to be effective.

University of Minnesota spinout Calyxt has entered the public markets in a flotation that resulted in the share price climbing from $8 to $11.25 on the first day of trading.